Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil

Sakuma,Kaname; Tanaka,Akira; Mataga,Izumi

doi:10.3892/ol.2016.5238

Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil

Authors:
- Kaname Sakuma
- Akira Tanaka
- Izumi Mataga
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Niigata 951‑8580, Japan, Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry, Tokyo 102‑8159, Japan
Published online on: October 11, 2016 https://doi.org/10.3892/ol.2016.5238
Pages: 4643-4650

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The collagen gel droplet-embedded culture drug sensitivity test (CD‑DST) is an anticancer drug sensitivity test that uses a method of three-dimensional culture of extremely small samples, and it is suited to primary cultures of human cancer cells. It is a useful method for oral squamous cell carcinoma (OSCC), in which the cancer tissues available for testing are limited. However, since the optimal contact concentrations of anticancer drugs have yet to be established in OSCC, CD‑DST for detecting drug sensitivities of OSCC is currently performed by applying the optimal contact concentrations for stomach cancer. In the present study, squamous carcinoma cell lines from human oral cancer were used to investigate the optimal contact concentrations of cisplatin (CDDP) and fluorouracil (5‑FU) during CD‑DST for OSCC. CD‑DST was performed in 7 squamous cell carcinoma cell lines derived from human oral cancers (Ca9‑22, HSC‑3, HSC‑4, HO‑1‑N‑1, KON, OSC‑19 and SAS) using CDDP (0.15, 0.3, 1.25, 2.5, 5.0 and 10.0 µg/ml) and 5‑FU (0.4, 0.9, 1.8, 3.8, 7.5, 15.0 and 30.0 µg/ml), and the optimal contact concentrations were calculated from the clinical response rate of OSCC to single‑drug treatment and the in vitro efficacy rate curve. The optimal concentrations were 0.5 µg/ml for CDDP and 0.7 µg/ml for 5‑FU. The antitumor efficacy of CDDP at this optimal contact concentration in CD‑DST was compared to the antitumor efficacy in the nude mouse method. The T/C values, which were calculated as the ratio of the colony volume of the treatment group and the colony volume of the control group, at the optimal contact concentration of CDDP and of the nude mouse method were almost in agreement (P<0.05) and predicted clinical efficacy, indicating that the calculated optimal contact concentration is valid. Therefore, chemotherapy for OSCC based on anticancer drug sensitivity tests offers patients a greater freedom of choice and is likely to assume a greater importance in the selection of treatment from the perspectives of function preservation and quality of life, as well as representing a treatment option for unresectable, intractable or recurrent cases.

View Figures

View References

1	Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
2	Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C and Schalhorn A: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 16:1318–1324. 1998.PubMed/NCBI
3	Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M and Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 88:876–883. 2000. View Article : Google Scholar : PubMed/NCBI
4	Fuwa N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, Sasaoka M, Kimura Y and Morita K: A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer. 89:2099–2105. 2000. View Article : Google Scholar : PubMed/NCBI
5	Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, et al: TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
6	Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003. View Article : Google Scholar : PubMed/NCBI
7	Suzuki M, Ishikawa H, Tanaka A and Mataga I: Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. Human Cell. 24:21–29. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kato T: Phase II study of CIS-diamminedichloroplatinum (II) by collaborative study. Gan To Kagaku Ryoho. 9:694–701. 1982.(In Japanese). PubMed/NCBI
9	Noda K, Takeuchi S, Kurihara S, Sugawa T, Kato T, Ikeda M, Kanazawa K, Tsutsui F, Yamamoto K, Umezu J, et al: Phase II study of cisplatin in cervical and endometrial carcinomas. Gan To Kagaku Ryoho. 14:1129–1135. 1987.(In Japanese). PubMed/NCBI
10	Ishibiki K, Kumai K, Kodaira S, Abe O, Yamamoto K, Oouchi T, Fukaya Y, Kimura K, Takamatsu K, Ootsuka E, et al: Phase II study with cisplatin in advanced stomach and colon carcinoma. Cooperative study group of cisplatin for stomach and colon carcinoma. Gan To Kagaku Ryoho. 16:3185–3193. 1989.(In Japanese). PubMed/NCBI
11	Kondo T, Kubota T, Tanimura H, Yamaue H, Akiyama S, Maehara Y, Tanigawa N, Kitajima M and Takagi H: Cumulative results of chemosensitivity tests for antitumor agents in Japan. Japan Research Society for Appropriate Cancer Chemotherapy. Anticancer Res. 20:2389–2392. 2000.PubMed/NCBI
12	Rygaard J and Povlsen CO: Heterotransplantation of a human malignant tumor to ‘Nude’ mice. Acta Pathol Microbiol Scand. 77:758–760. 1969. View Article : Google Scholar : PubMed/NCBI
13	Bogden AE, Cobb WR, Lepage DJ, Haskell PM, Gulkin TA, Ward A, Kelton DE and Esber HJ: Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: Six-day subrenal capsule assay. Cancer. 48:10–20. 1981. View Article : Google Scholar : PubMed/NCBI
14	Kobayashi H, Tanisaka K, Kondo N, Mito Y, Koezuka M, Yokouchi H, Higashiyama M, Kodama K, Doi O, Yamada M, et al: Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness. Gan To Kagaku Ryoho. 22:1933–1939. 1995.(In Japanese). PubMed/NCBI
15	Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
16	Kobayashi H: Development of a new in vitro chemosensitivity test using collagen gel droplet culture and image analysis for clinical usefulness. Recent Results Cancer Res. 161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
17	Hanatani Y, Kobayashi H, Kodaira S, Takami H, Asagoe T and Kaneshiro E: An in vitro chemosensitivity test for gastric cancer using collagen gel droplet embedded culture. Oncol Rep. 7:1027–1033. 2000.PubMed/NCBI
18	Araki Y, lsomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J. 46:163–166. 1999. View Article : Google Scholar : PubMed/NCBI
19	Shintani S, Hino S, Nakashiro K and Hamakawa H: Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions. Gan To Kagaku Ryoho. 33:357–360. 2006.(In Japanese). PubMed/NCBI
20	Matsumoto Y, Tamiya T and Nagano S: Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest. 52:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
21	Selvakumaram M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63:1311–1316. 2003.PubMed/NCBI
22	Bartolucci R, Wei J, Senchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, et al: XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer. 10:47–52. 2009. View Article : Google Scholar : PubMed/NCBI
23	Park JS, Yoon S Young, Kim JM, Yeom YI, Kim YS and Kim NS: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 214:19–33. 2004. View Article : Google Scholar : PubMed/NCBI
24	Koezuka M, Kondo N, Kobayashi H, Hara S, Yasutomi M, Nishida S, Hashimoto S and Asano H: Drug sensitivity test for human cancer-cells using collagen gel embedded culture and image analysis. Int J Oncol. 2:953–959. 1993.PubMed/NCBI
25	Nagai N, Minamikawa K, Mukai K, Hirata E, Komatsu M and Kobayashi H: Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test. Anticancer Drugs. 16:525–531. 2005. View Article : Google Scholar : PubMed/NCBI
26	Inuyama Y and Takeda C: A cooperative phase II study of cisplatin in patients with head and neck cancer. Gan To Kagaku Ryoho. 13:232–238. 1986.(In Japanese). PubMed/NCBI
27	Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 10:257–263. 1992.PubMed/NCBI
28	Inaba M, Kobayashi T, Tashiro T and Sakurai Y: Pharmacokinetic approach to rational therapeutic dose for human tumor-bearing nude mice. Jpn J Cancer Res. 79:509–516. 1988. View Article : Google Scholar : PubMed/NCBI
29	Inaba M: Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents. Gan To Kagaku Ryoho. 18:1449–1456. 1991.(In Japanese). PubMed/NCBI
30	Geran RI, Greenberg NH, Macdonald MM, et al: Protocols against animal tumors and other biological systems. Cancer Chemother Rep. 3:51–57. 1972.
31	Kawamura M, Inoue Y, Oyama T and Kobayashi K: Chemosensitivity test for uresectable non-small cell lung cancer. Nihon Geka Gakkai Zasshi. 103:229–232. 2002.(In Japanese). PubMed/NCBI
32	Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. lnt J Cancer. 98:450–455. 2002.
33	Kondo T, lmamura T and lchibashi H: In vitro test for sensitivity of tumor to carcinostatic agents. Gan. 57:113–121. 1966.PubMed/NCBI
34	Salomon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS and Moon TE: Quantitation of differential sensitivity of human-tumor stem cell to anticancer drugs. N Engl J Med. 298:1321–1327. 1978. View Article : Google Scholar : PubMed/NCBI
35	Kobayashi H: CD-DST (Collagen gel droplet embedded culture drug sensitivity test). Oncology Chemotherapy. 16:231–235. 2000.
36	Shintani S, Hino S, Nakashiro K and Hamakawa H: Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions. Gan To Kagaku Ryoho. 33:357–360. 2006.PubMed/NCBI
37	Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C and Roig B: Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control. 10:297–305. 2003.PubMed/NCBI
38	Reardon JT, Vaisman A, Chaney SG and Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59:3968–3971. 1999.PubMed/NCBI
39	Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F and Maehara Y: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer. 121:895–900. 2007. View Article : Google Scholar : PubMed/NCBI
40	Simon GR, Sharma S, Cantor A, Smith P and Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 127:978–983. 2005. View Article : Google Scholar : PubMed/NCBI
41	Fukushima M, Nomura H, Murakami Y, Shirasaka T and Aiba K: Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro in vivo. Gan To Kagaku Ryoho. 23:721–731. 1996.(In Japanese). PubMed/NCBI
42	Sakamoto K, Sugimoto Y, Miyadera K, Oka T and Fukushima M: Preparation of anti-OPRT antibody for immunochemical detection. Gan To Kagaku Ryoho. 32:653–658. 2005.(In Japanese). PubMed/NCBI
43	Ishida H, Shirakawa K, Ohsawa T, Sobajima J, Hayashi Y, Nakada H, Yokoyama M and Hashimoto D: Expression of mRNA levels of thymidilate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer-relationships among mRNA levels in association with response to 5-FU based treatment. Gan To Kagaku Ryoho. 32:1929–1934. 2005.(In Japanese). PubMed/NCBI
44	Yamada T, Tanaka N, Yokoi K, Ishikawa N, Seya T, Kanazawa Y, Shirakawa T, Ohkawa K, Koizumi M, Ohaki Y, et al: Correlation between clinical pathologic factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) in colorectal cancer. Gan To Kagaku Ryoho. 33:789–793. 2006.(In Japanese). PubMed/NCBI
45	Watanabe M, Satomi T, Matuda K, et al: Relationship between expression of enzymes activating fluoropyrimidine anti-tumor agents and response to the agents in oral squamous cell carcinoma. Japanese Journal of Head and Neck Cancer. 34:498–502. 2008.